Dice Thinks It Holds An Ace With Oral IL-17 Inhibitor In Psoriasis

The company believes it has a potential best-in-class oral drug for psoriasis in development following positive first-in-human clinical trial data. A larger Phase II study is needed.

dice
Dice Therapeutics' oral IL-17 inhibitor showed encouraging early data • Source: Shutterstock

DICE Therapeutics, Inc. believes it could have a best-in-class oral drug in development for psoriasis based on positive data from a Phase I clinical trial testing DC-806, an oral small molecule antagonist of interleukin-17. The data are early, but the company's stock price shot up 79% to open 11 October at $44.18 on the news given how lucrative the commercial opportunity for effective oral options could be in a category dominated by injectable drugs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D